Related Experiment Video
Updated: Sep 7, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Management of hypertension in advanced kidney disease
Panagiotis I Georgianos1, Rajiv Agarwal2
1Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Insights
Newer therapies improve hypertension management in advanced chronic kidney disease (CKD). Potassium binders aid spironolactone use, novel nonsteroidal mineralocorticoid receptor antagonists (MRAs) show promise, and chlorthalidone effectively lowers blood pressure.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hypertension is a significant complication in patients with advanced chronic kidney disease (CKD).
- Managing blood pressure in CKD patients is challenging due to risks of hyperkalemia and reduced drug efficacy.
Purpose of the Study:
- To review recent advancements in pharmacotherapy for hypertension in patients with advanced CKD.
- To highlight novel therapeutic strategies for improved blood pressure control in this high-risk population.
Main Methods:
- Review of recent clinical trials including AMBER, BLOCK-CKD, and CLICK.
- Analysis of pharmacologic interventions targeting blood pressure and potassium levels in CKD patients.
Main Results:
- Patiromer, a potassium binder, facilitated spironolactone use and improved blood pressure control in patients with resistant hypertension and advanced CKD.
- The novel nonsteroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 demonstrated significant blood pressure reduction with minimal hyperkalemia risk in advanced CKD.
- Chlorthalidone, a thiazide-like diuretic, effectively lowered 24-hour ambulatory systolic blood pressure in patients with stage 4 CKD and uncontrolled hypertension.
Conclusions:
- New potassium-binding agents enable more consistent spironolactone therapy.
- Novel nonsteroidal MRAs offer a potentially improved benefit-risk profile for hypertension management in advanced CKD.
- Chlorthalidone presents a viable option for blood pressure reduction in high-risk CKD patients.
Purpose Of Review:
The aim of this study was to present recent developments in pharmacotherapy of hypertension in patients with advanced chronic kidney disease (CKD).
Recent Findings:
In the AMBER trial, compared with placebo, the potassium-binder patiromer mitigated the risk of hyperkalaemia and enabled more patients with uncontrolled resistant hypertension and stage 3b/4 CKD to tolerate and continue spironolactone treatment; add-on therapy with spironolactone provoked a clinically meaningful reduction of 11-12 mmHg in unattended automated office SBP over 12 weeks of follow-up. In the BLOCK-CKD trial, the investigational nonsteroidal mineralocorticoid-receptor-antagonist (MRA) KBP-5074 lowered office SBP by 7-10 mmHg relative to placebo at 84 days with a minimal risk of hyperkalaemia in patients with advanced CKD and uncontrolled hypertension. The CLICK trial showed that the thiazide-like diuretic chlorthalidone provoked a placebo-subtracted reduction of 10.5 mmHg in 24-h ambulatory SBP at 12 weeks in patients with stage 4 CKD and poorly controlled hypertension.
Summary:
Enablement of more persistent spironolactone use with newer potassium-binding agents, the clinical development of novel nonsteroidal MRAs with a more favourable benefit-risk profile and the recently proven blood pressure lowering action of chlorthalidone are three therapeutic opportunities for more effective management of hypertension in high-risk patients with advanced CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management
Hypertension V: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Nephrotic Syndrome III : Nursing Management

